Supplier News

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

BlueAllele has been granted a US patent for its advanced gene-editing technology, PALIDON, which is compatible with existing gene editing nucleases and delivery systems.

Syngene’s additions include a new microbial facility and an expanded mammalian facility.

Biotage’s new facility in Cardiff, UK, will produce lipids using large-scale flash purification.

Rentschler Biopharma has broken ground nearby its Milford, Mass., site where it will build its new multi-product manufacturing facility for commercial production of complex molecules.

Lykan Bioscience and Vineti will combine their capabilities to streamline process development and manufacturing to move cell therapies through clinical phases to commercialization.

A collaboration between Aldevron and Ginkgo Bioworks has resulted in a manufacturing enhancement that can improve production of an enzyme used for mRNA therapeutics.

Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform.

The Just - Evotec Biologics facility in Redmond, Wash., uses the company’s J.POD technology.

Nobelpharma has come to terms on an agreement to use ProBioGen’s vaccine manufacturing platform AGE1.CR.plX.

Datwyler offers the StarterPack packaging system designed to aid in the development of parenteral drug packaging.

Kyowa Pharmaceutical Industry and Bora Pharmaceuticals have announced a partnership to produce generic-drug product for filing in Japan.

Emergent BioSolutions has been granted approval from FDA to ship certain lots of their AstraZeneca vaccine.

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

Novavax and European Commission have finalized an agreement to purchase up to 200 million doses of a COVID-19 vaccine.

Catalent finalizes their acquisition of iPSC developer and manufacturer RheinCell Therapeutics.

TriRx continues to expand its manufacturing capabilities with the acquisition of the Elanco Animal Health Facility in Shawnee, Kansas.

BMG Pharma's clinical trial has demonstrated positive results in the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse as treatments for asymptomatic COVID-19 patients.

Evonik has acquired the German biotech company JeNaCell, expanding its biomaterials portfolio.

Nanoform and Boehringer Ingelheim have executed a master services agreement in relation to pre-clinical development projects.

WuXi STA has finalized its acquisition of Bristol Myers Squibb’s drug product manufacturing facility based in Couvet, Switzerland.

Bristol Myers Squibb has been granted approval by the European Commission for Opdivo (nivolumab) as an adjuvant treatment

Bioiberica has received certification of its CSR management system as aligned with the United Nations Sustainable Development Goals.

Sanofi has acquired Translate Bio in a bid to further their mRNA research.

DisperSol and Catalent announce manufacturing collaboration to accelerate DisperSol’s pharmaceutical production.

Regeneron and AstraZeneca have entered an agreement to create a small-molecule medicine designed to treat obesity.

Emergent BioSolutions is being allowed to restart manufacturing operations for the J&J COVID-19 vaccine at its Bayview, Baltimore, Md., facility.

VICO Therapeutics’ drug candidate, VO659, for treating Huntington’s Disease was granted orphan drug designation by FDA.

Thermo Fisher Scientific has added a new suite of immune repertoire assays that offers high detection rates of malignant clones, allowing researchers to better assess blood cancers.

ERS Genomics and Japan SLC have signed a non-exclusive license agreement, allowing Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.